Trial Profile
Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs MEDI 570 (Primary)
- Indications Cutaneous T-cell lymphoma; Follicular lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions; First in man
- 01 Mar 2024 Planned End Date changed from 31 Dec 2023 to 28 Feb 2025.
- 24 Feb 2023 Results (n=23) assessing the safety, pharmacokinetics, pharmacodynamics and clinical activity of MEDI-570 in T-cell non-Hodgkin's lymphomas, published in the Clinical Cancer Research.
- 18 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.